secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0000950170-25-040232
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics reports FY2024 revenue $105.8M, issues FY2025 guidance $118-128M; Phase 3 data due Q2 2025
--------------------------------------------------------------------------------

- FY2024 revenue $105.8M (down 6.8% YoY); net income $17.9M vs loss $85.5M in 2023 on absence of IPR&D charge.
- Non-GAAP adjusted net income $16.9M (down from $25.4M); cash $51.2M at year-end.
- FY2025 revenue guidance $118-128M (11-21% growth) driven by planned launches of nintedanib and avatrombopag in China.
- Pivotal Phase 3 trial of F351 in CHB-associated liver fibrosis topline data expected Q2 2025; U.S. Phase 2 in MASH planned.
- Appointed Ping Zhang as lead independent director; Songjiang Ma appointed Chairman of Gyre Pharmaceuticals board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000095017025040232/0000950170-25-040232-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000095017025040232/gyre-20250317.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-040232

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer